How drug companies are playing hardball with Australia’s PBS

International drug companies are testing Australia's resolve over medicine prices. Per The Conversation, they're demanding higher reimbursement for their drugs and threatening to withdraw from the market if negotiations don't go their way. Earlier this year, Eli Lilly refused to apply for its diabetes drug tirzepatide—sold as Mounjaro—to be subsidized through Australia's Pharmaceutical Benefits Scheme, after price talks broke down. Multiple sclerosis drugs have faced similar disputes; the government says those medicines will remain available during an ongoing review. This pressure reflects a broader shift: the US and UK recently agreed to a trade deal that requires the UK to raise what it pays for new pharmaceuticals, setting a precedent other nations are watching. Australia's system evaluates whether new medicines actually improve patient outcomes compared to existing treatments, not just their price. Analyses show roughly half of newly approved drugs offer no additional health benefit over what's already available. Australians already spend an average of one thousand two hundred fifty dollars per person yearly on medicines. At stake is whether pharmaceutical companies can use withdrawal threats to reshape how subsidized medicines reach patients.

Listen to this story

Hear this and more stories in a personalized audio briefing.

Open The Chonkerton